DOCSLIB.ORG

Healthcare Communications Vol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Healthcare Communications Vol Vol.Vol. 18, 20, No. No. 2, 3, 2009, 2011, ISSNISSN 1854-8466.1854-8466. Healthcare communications Vol. 20, No. 3, 2011 The Write Stuff EMWA Executive Committee Journal insights The Write Stuff is the offi cial publication of the European Medical Writers Asso- ciation. It is issued 4 times a year and aims to provide EMWA members with relevant, President: informative and interesting articles and news addressing issues relating to the broad Rita Wellens arena of medical writing. We are open to contributions from anyone whose ideas can Wellens Clinical Research Consulting complement these aims, but opinions expressed in individual articles are those of the Rillaar, Belgium authors and are not necessarily those held by EMWA as an association. [email protected] Articles or ideas should be submitted to the Journal Editor (see below) or another member of the Editorial Board. Vice President: Susan Batti Subscriptions Subscriptions are included in EMWA membership fees. By writing to [email protected] Premier Research Germany Ltd., Darmstadt, Germany, non-members can subscribe at an annual rate of: [email protected] • €35 within Europe • €50 outside Europe Treasurer: Instructions for contributors Gillian Pritchard • The Write Stuff typically publishes articles of 800–2500 words although long- Sylexis Limited er pieces or those with tables or graphics will be considered. Dundee, UK • All articles are subject to editing and revision by the Editorial Board. Any chang- [email protected] es will be discussed with the author before publication. • Submissions should include the full address of the author, including the telephone and fax numbers and e-mail address. Suitable quotes for side boxes can be indi- Honorary Secretary: cated or they can be selected by the Editorial Board. Sarah Choudhury • Material should be submitted by e-mail as an MS Word fi le using Times New Medical writer Roman (or equivalent), 10 point size, and single spacing. Letchworth Garden City, UK • Published articles generally include a recent photograph of the author (portrait [email protected] picture, CV or passport style, min. 360 x 510 pixels). Timelines Public Relations Offi cer: Month Deadline Deadline Farid Khalfi distributed for receipt of articles for receipt of adverts Guerbet March 1st January 15th February Roissy, France June 1st April 15th May [email protected] September 1st July 15th August December 1st October 15th November Website Manager: Shanida Nataraja Advertising rates (in euro, €) Axon Communications Corporate Private / Freelance members only London, UK [email protected] • Full page €1000 • Full page €200 • Half page €500 • Half page €100 Education Offi cer: Jo Whelan Behind the press Textpharm Ltd The Editorial Board Oxford, UK [email protected] Associate editor Phil Laventhal Board members Chris Priestley Richard Clark Conference Director Ursula Schoenberg Margaret Gray Sunethra Wimalasundera Andrea Rossi Medical writer Iain Patten Hatfi eld, UK Joselita T. Salita [email protected] Columnists Alistair Reeves Wendy Kingdom Alison McIntosh Journal Editor Françoise Salager-Meyer Elise Langdon-Neuner Karin Eichele Baxter BioScience Dianthus team Vienna, Austria Gabriele Berghammer [email protected] Greg Morley Freelance forum columnists Raquel Billiones Sam Hamilton EMWA Head Offi ce Chester House, 68 Chestergate, Macclesfi eld, Disclaimer Cheshire, SK11 6DY, UK The views and opinions expressed in The Write Stuff are those of the individual Tel: +44 (0)1625 664534, Fax: +44 (0)1625 664510 authors and do not necessarily represent those of the European Medical Writers As- [email protected] EMWA website: www.emwa.org sociation or its Executive Committee. The Write Stuff is printed on 100% recycled paper. 138 The Journal of the European Medical Writers Association The Write Stuff Vol. 20, No. 3, 2011 TOC Healthcare communications Vol 20, No. 3, 2011 Catherine Mary Ursula Schoenberg Healthcare communications: Out of Hours: On Chekhov, Figuring out the outside view 144 elephants and writing for pleasure 178 Matthew Doherty Diana Raffelsbauer Communication and collaboration— Going freelance: Infl uencing behaviour through effective The third of a series of interviews 180 partnership and information sharing 146 Translation Section Daniele La Barbera, Caterina La Cascia, Alice Mulè, Gabriele Berghammer Salvatore Raspanti, Andrea Rossi Outsourcing translations: Clinician–patient relationship The hows and whys of it 201 and adherence to treatment 150 Aksel Seyahi and Ariel Surface Trevor Lane Bilingual copyediting: Journal impact factor facts 153 Beyond translation 208 Christina Johnsen How to cope with the transition from being a sedated academic to a proactive but poor medical writer sprout 155 Neville W Goodman Prepositions and their role in Abba’s downfall 157 Alistair Reeves Since you mention Abba... 159 Julia Boese My way to medical writing 161 Joselita T. Salita Cover photograph Evaluating the return Cover photograph from Nadja Meister ([email protected]) on attending a conference 163 Graphic design on pages 166, 175, 197 and 207 by Anders Holmqvist Stephen Gilliver ([email protected]) Spotlight on Sweden: How English is changing and replacing Swedish 165 Regular features From the Editor’s desk 140 Message from the President 143 Freelance Section Webscout 168 Anders Holmqvist Journal watch 169 The Berlin conference—A review Good writing practice 171 from a non-writer 174 Words, Grammar & Co 183 For regulatory writers 188 Biomedical publishing shorts 190 Brian Bass and Sam Hamilton Medical journalism 194 Opposing views: Manuscript writers 199 Project versus hourly rates 176 Vital signs 209 The Journal of the European Medical Writers Association 139 Vol. 20, No. 3, 2011 The Write Stuff From the Editor’s desk Healthcare communications: A question of defi nition by Mario Nacinovich and Elise Langdon-Neuner Most EMWA members are employed directly or indirectly was “a term used by many, but it lacks a precise defi ni- by the pharmaceutical industry and their main remit is to tion” [3]. In a somewhat dramatic shift in thinking, Mai- produce documents for the regulatory authorities or docu- bach and Holtgrave later espoused that the term included ments that inform the medical community about drug prod- the use of “communication techniques and technologies to ucts, e.g. through papers published in biomedical journals. (positively) infl uence individuals, populations, and organi- This issue of TWS introduces medical writers who work in zations” [4]. More recently, Ishikawa and Kiuchi helped industry to healthcare communications. When the words to simplify our understanding by stating, “Health commu- ‘health’ and ‘communication’ are associated in a defi ni- nication consists of interpersonal or mass communication tion, we are to my mind talking about a fi eld that should activities focused on improving the health of individuals cross paths with medical writers. But do medical writers and populations” [5]. For many in our emerging fi eld, the work in healthcare communication? To answer this ques- following integrated defi nition has become the new gold- tion we need to establish the precise defi nition of health standard defi nition of health communication—it is a “mul- communications and for this I enlisted Mario Nacinovich’s tifaceted and multidisciplinary approach to reach different help. Mario is the editor in chief of the Journal of Com- audiences and share health-related information with the munication in Healthcare, Managing Director of AXON goal of infl uencing, engaging, and supporting individuals, Communications, and adjunct faculty at Boston University communities, health professionals, special groups, policy- and he explores the concept of health communications in makers and the public to champion, introduce, adopt, or the following paragraph. sustain a behaviour, practice, or policy that will ultimately Ongoing review and appraisal of health communications improve health outcomes” [6]. initiatives have confi rmed the value of adopting specifi c Three feature articles in this issue of TWS illustrate the communication strategies to promote health and ultimate- gold-standard defi nition of healthcare communications and ly facilitate the processes in the prevention and treatment highlight its diversity. Catherine Mary’s article probes the of disease. Effective health communications strategies elements necessary to engender public trust in healthcare worldwide unite varied approaches, theories and frame- messages issued by governmental authorities, healthcare works from a range of disciplines, including but not limit- professionals and journalists, by reference to the H1N1 in- ed to communication, public relations, behavioural scienc- fl uenza pandemic. Daniele La Barber and colleagues look es, social marketing, and health education. The defi nition in their article at how healthcare professionals can commu- and practical aspects of these disciplines can be considered nicate more effectively with their patients. The third article, empiric, while the defi nition of ‘health communication’ has written by Matthew Doherty of Medicines for Malaria Ven- not been universally accepted nor ingrained in its practi- ture, explains the role of Product Development Partnerships tioners. According to the Offi ce of Disease Prevention and in developing drugs that are not profi table for the pharma- Health Promotion in the United States, “Health communi- ceutical industry, and the importance and different aspects cation is the study and use of communication strategies to of communication
Load more

Recommended publications
  • Medical Writing Management Vol
    Vol.Vol. 18, 20, No. No. 2, 4, 2009, 2011, ISSNISSN 1854-8466.1854-8466. Medical writing management Vol. 20, No. 4, 2011 The Write Stuff EMWA Executive Committee Journal insights The Write Stuff is the offi cial publication of the European Medical Writers Asso- ciation. It is issued 4 times a year and aims to provide EMWA members with relevant, President: informative and interesting articles and news addressing issues relating to the broad Rita Wellens arena of medical writing. We are open to contributions from anyone whose ideas can Wellens Clinical Research Consulting complement these aims, but opinions expressed in individual articles are those of the Rillaar, Belgium authors and are not necessarily those held by EMWA as an association. Articles or ideas should be submitted to the Journal Editor (see below) or another [email protected] member of the Editorial Board. Vice President: Subscriptions Please contact Maney Publishing’s Customer Services & Subscriptions Team at sub- Susan Batti [email protected] for subscription information or view http://www.maney. Premier Research Germany Ltd., co.uk/journals/mew. Darmstadt, Germany, [email protected] Instructions for contributors • The Write Stuff typically publishes articles of 800–2500 words although long- er pieces or those with tables or graphics will be considered. Treasurer: • All articles are subject to editing and revision by the Editorial Board. Any chang- Gillian Pritchard es will be discussed with the author before publication. Sylexis Limited • Submissions should include the full address of the author, including the telephone Dundee, UK and fax numbers and e-mail address. Suitable quotes for side boxes can be indi- [email protected] cated or they can be selected by the Editorial Board.
    [Show full text]
  • (FAQ) About Statin Adverse Effects
    Frequently Asked Questions (FAQ) about Statin Adverse Effects Table of Contents Frequently Asked Questions about Statin Adverse Effects ................................................ 3 Introduction......................................................................................................................... 3 What are the names of the Statin drugs?......................................................................... 4 What is the “Statin Study”? ............................................................................................ 4 Where can I look to find information on research studies of statin drugs? .................... 5 Why does my physician have such a difficult time believing that my physical problems might be an adverse effect of Lipitor or one of the other statins? .................................. 5 OK, I understand the doctor’s need to read clinical study results, but where can I find out what other people are experiencing in plain language, and maybe share my experiences?....................................................................................................................7 Are there any books on the topic?................................................................................... 7 What are the Liptior warnings and side-effects listed by the manufacturer on the physicians’ information?................................................................................................. 8 What are the Lipitor Adverse Events in Placebo-Controlled Studies listed by Pfizer in the Physician’s
    [Show full text]
  • Industry-Corrupted Psychiatric Trials1
    Psychiatr. Pol. 2017; 51(6): 993–1008 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: https://doi.org/10.12740/PP/80136 Industry-corrupted psychiatric trials1 Jay D. Amsterdam1, Leemon B. McHenry 2, Jon N. Jureidini3 1Depression Research Unit, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 2Department of Philosophy, California State University, Northridge, California 3Critical and Ethical Mental Health Research Group, Robinson Research Institute, University of Adelaide, Australia Summary The goal of this paper is to expose the research misconduct of pharmaceutical industry- sponsored clinical trials via three short case studies of corrupted psychiatric trials that were conducted in the United States. We discuss the common elements that enable the misrepre- sentation of clinical trial results including ghostwriting for medical journals, the role of key opinion leaders as co-conspirators with the pharmaceutical industry and the complicity of top medical journals in failing to uphold standards of science and peer review. We conclude that the corruption of industry-sponsored clinical trials is one of the major obstacles facing evidence-based medicine. Key words: antidepressants, citalopram, clinical trials, depression, ghostwriting, key opi- nion leaders, paroxetine, research misconduct, selective reporting Introduction As former editor of the New England Journal of Medicine, Marcia Angell reported in 2008: Over the past 2 decades, the pharmaceutical
    [Show full text]
  • Access to Information and Medicines Regulation in New Zealand
    549 ACCESS TO INFORMATION AND MEDICINES REGULATION IN NEW ZEALAND Amy Hill* This article explores a significant issue in the regulatory regime for medicines in New Zealand and around the world: the deficit of information about medicines available to doctors, patients and independent researchers. In New Zealand, while some generic (off-patent) drugs are manufactured domestically, the major suppliers are large multinational companies. Similarly, clinical trials to establish a drug's effectiveness, safety and quality are predominantly undertaken overseas. Much of the information about safety, efficacy and quality of drugs is held and controlled by pharmaceutical companies and regulators. This article proposes ways in which public access to information about medicines can be improved. I INTRODUCTION This article examines the regulatory regime for medicines in New Zealand, and the future Trans- Tasman regime that Australia and New Zealand will transition into. It then goes on to explain the issue of hidden data and lack of publicly available information about medicines and clinical trials. In Parts IV and V, it briefly discusses the way that information about medicines is provided by the pharmaceutical industry and explores avenues for making regulatory changes to improve transparency. Finally, this article explores way in which administrative law may also assist in improving transparency in this area. * BA/LLB (Hons). Solicitor at Chapman Tripp in Wellington. The author would like to thank Professor Bill Atkin for his supervision and support, and the interviewees who were so generous with their time and with sharing information. A small number of people with relevant expertise were approached and interviewed for this article.
    [Show full text]
  • Jay Amsterdam, Filed a 24-Page Complaint With
    BAUM. HEDLUND, ARISTEI & GOLDMAN A Professional Corporation 12100 Wilshire Boulevard, Suite 950 Washington, D.C. Office Philadelphia Office 1250 24th Street, N.W. Los Angeles, California 90025-7114 1 500 Market Street Suite 300 Tel (310) 207-3233 12th Floor East Tower Washington, D.C. 20037-1124 Philadelphia, PA 19102-2100 Tel (202) 466-0513 Fax (310) 820-7444 Tel (215) 665-5659 Fox (202) 466-0527 www.baumhedlundlaw.com Fox (215) 569-8228 June 25, 2012 Donald Wright, MD MPH via Federal Express Acting Director, Office of Research Integrity U.s. Department of Health and Human Services Office of Research Integrity 1101 Wootton Parkway, Suite 750 Rockville, Maryland 20852 Tel: 240-453-8200 Fax: 301-443-5351 Email: [email protected] The challenge of pursuing science in a morally justified way is one that even) generation must take up. - Amy Gutmann and James Wagner Re: Complaint of Scientific Misconduct against Dwight L. Evans, Laszlo Gyulai, Charles Nemeroff, Gary S. Sachs and Charles L. Bowden Dear Dr. Wright: On behalf of Dr. Jay D. Amsterdam, Professor of Psychiatry at the University of Pennsylvania, a charge of research misconduct was submitted to your office against Dr. Dwight L. Evans, Professor of Psychiatry and Chairman of the Department of Psychiatry at the University of Pennsylvania, Dr. Laszlo Gyulai, Associate Professor of Psychiatry at the University of Pennsylvania, Dr. Charles B. Nemeroff, Professor of Psychiatry and Chairman of the Department of Psychiatry at the University of Miami, Dr. Gary S. Sachs, Professor of Psychiatry at Harvard University, and Dr. Charles L. Bowden, Professor of Psychiatry and Chairman of the Department of Psychiatry at the University of Texas at San Antonio.
    [Show full text]
  • The Ethics of Pharmaceutical Industry Influence in Medicine
    The Ethics of Pharmaceutical Industry Influence in Medicine The Ethics of Pharmaceutical Industry Influence in Medicine 1 2 The Ethics of Pharmaceutical Industry Influence in Medicine THE ETHICS OF PHARMACEUTICAL INDUSTRY INFLUENCE IN MEDICINE By *Omar Sultan Haque, *Julian De Freitas, Harold J. Bursztajn, Lisa Cosgrove, Abilash A. Gopal, Robindra Paul, Itay Shuv-Ami & Samuel Wolfman [*equal contributors] THE UNESCO CHAIR IN BIOETHICS Chairholder: Prof. Amnon Carmi The International Center for Health, Law and Ethics Faculty of Law, University of Haifa, Israel The Ethics of Pharmaceutical Industry Influence in Medicine 1 May 2013 UNESCO Chair in Bioethics Office e-mail: [email protected] ISBN 978-965-444-035-6 No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written and signed permission of UNESCO Chair in Bioethics. As a rule, permission will be given to the review, abstraction, reproduction and translation of this publication, in part or in whole, but not for sale nor for use in conjunction with commercial purposes, subject to acknowledgement of original publication by the UNESCO Chair in Bioethics, the University of Haifa, Israel. The views expressed in this document are solely the responsibility of the authors and do not necessarily represent the view of organizations with which they are associated. COPYRIGHT © UNESCO Chair in Bioethics Graphic design: Vered Bitan Studio Publication:
    [Show full text]
  • Geoff Smith,1 Jon Nilsen,1 Shawn Lee,1 Mee Rhan Kim,1 Dikran Toroser
    Monitoring the External Publication Environment (MEPE): Identifying and Communicating Significant Developments to NITOR O A M N A L Excellence Y Z In Medical E Key Stakeholders in a Corporate Setting Publishing MEPE 1 1 1 1 1 1 2 1 1 E M N R Geoff Smith, Jon Nilsen, Shawn Lee, Mee Rhan Kim, Dikran Toroser, Erica Rockabrand, Lucy Hyatt, Larry Kovalick, Juli Clark SU FO RE IN 1Amgen Inc., Thousand Oaks, CA, USA; 2Amgen (Europe) GmbH, Zug, Switzerland ABSTRACT METHODS RESULTS SUMMARY Objective: Knowledge of medical publication policies, issues, and trends is critical for Task Force Standard Review and Assessment Procedures Figure 1. Process Map Four Updates on Key Developing Issues Were Prepared by Figure 2. The Articles That Were the Subjects of the Updates • The rapidly changing environment of medical publishing requires that pharmaceutical executives and research and development personnel in the drug and • MEPE tracks trending issues in medical publications issued by: the MEPE Task Force Over the Past Year Had Comparable External Impact to Similar Articles companies relying on journal publications to communicate science-based device industries who provide input on industry-sponsored publications. A poster Ideal Timeline Person(s) Responsible Published in the Same Venue findings from their research activities keep aware of updates to presentation at ISMPP 2011 outlined our company’s efforts to provide such updates to – Journals Event MEPE Team Member 1. Merck amends publication policy to proactively provide study publication policies and current publication-related issues internal stakeholders by means of a dedicated task force. Our task force is now – Universities entering its third year of service.
    [Show full text]
  • UNITED STATES DISTRICT COURT EASTERN DISTRICT of WISCONSIN UNITED STATES of AMERICA, and the STATE of WISCONSIN, Ex Rel. DR
    UNITED STATES DISTRICT COURT EASTERN DISTRICT OF WISCONSIN UNITED STATES OF AMERICA, and THE STATE OF WISCONSIN, ex rel. DR. TOBY TYLER WATSON, Plaintiffs, v. Case No. 11-CV-236-JPS JENNIFER KING VASSEL, Defendant. RELATOR'S RESPONSE TO DOCUMENT NUMBERS: 159- Motion in Limine to Preclude any Reference that the Prescription of Off-Label Use of FDA Approved Prescription Medication was Medicaid Fraud; 161- Motion in Limine to Preclude Reference that this Lawsuit Provided Notice that Dr. King Should Have Changed Her Practice; 163- Amicus Brief by Wisconsin Medical Society; 165- Motion in Limine to Preclude Certain Witnesses of the Plaintiff from Testifying about Liability, Causation, or Damages; 169- Motion in Limine to Permit Reference to Other Physicians that Treated N.B. Prior to Dr. King; 170- Motion in Limine to Exclude Evidence of Geodon Prescriptions; and Relator Dr. Toby Tyler Watson (Dr. Watson) hereby responds to Document Numbers 159, 161, 163, 165, 169, 170 and 174, all filed on November 25 or 26, 2013. I. Document Number 159 -- Motion in Limine to Preclude any Reference that the Prescription of Off-Label Use of FDA Approved Prescription Medication was Medicaid Fraud In Document Number 159, Dr. King's Motion in Limine to Preclude any Reference that the Prescription of Off-Label Use of FDA Approved Prescription Medication was Medicaid Fraud, she continues to misstate Dr. Watson's position in a number of ways. First, as has been Case 2:11-cv-00236-JPS Filed 11/29/13 Page 1 of 22 Document 177 repeatedly pointed out, Dr. Watson has never asserted, nor is he asserting now, that all off-label use of drugs when presented to Medicaid are false claims.
    [Show full text]
  • Health Myths Exposed
    Health Myths Exposed - 2nd Edition - By Shane Ellison, M.Sc. How Western Medicine Undermines Your Health Courtesy of: TABLE OF CONTENTS Preface……………………………………………………………………….6 Myth #1 ─ FDA-Approved Drugs are Safe and Effective……………8 Dangerous Drugs Approved by the FDA....................................................... 8 Heal Yourself - Nature’s Antidepressant....................................................11 Dangerous FDA-Approved Drugs Given to Children...................................11 Myth: Children are Exempt from Vaccines by Public Schools .............................12 Stimulants 101...........................................................................................12 FDA-Approved A Lifetime of Health ....................................................................................12 drugs are safe and Myth #2 - Drug Approval is Based on Science………………………..13 effective. How Drug Companies took over the FDA...................................................13 Select Medical Doctors, Scientists and FDA Officials Reveal the Truth....14 Deadly Prescription Drugs – More to Come ..............................................14 Myth #3 - Drug Advertising Promotes Health Awareness…………..15 Fact: False Advertising of Cholesterol-Lowering Drugs ......................................15 FDA approval False Advertising of Hormone Replacement Therapy (HRT) Drugs ..........16 is simply a False Advertising of Ritalin and other CNS Stimulants .............................17 More False Advertising to Parents and Children .......................................18
    [Show full text]
  • Access to Information & Medicines Regulation in New
    AMY HILL EVIDENCE BASED MEDICINE? ACCESS TO INFORMATION & MEDICINES REGULATION IN NEW ZEALAND Faculty of Law Victoria University of Wellington 2013 2 Evidence Based Medicine? Access to Information and Medicines Regulation in New Zealand I Introduction 3 A Purpose 3 B Key Terms 4 C Methodology 5 II The Current Regime for Medicines Regulation 6 A Medsafe and the Medicines Act 1981 6 B Clinical Trials and Ethics Committees 8 II The ANZTPA 9 A Development 10 B The ANZTPA Regulatory Scheme 13 IV The Information Deficit in Medicine 17 A Hidden Data and its Impact on Public Health 18 B Health and Disability Service Consumers’ Rights 21 C Clinical Trials Register 23 D Information and Medsafe 24 E Justifications for Restricting Public Access to Clinical Study Report s 25 F Positive Reasons for Disclosure 29 V Information and the Pharmaceutical Industry 30 A Flawed Trials and Hidden Data 30 B Medical Writing 31 C Direct to Consumer Advertising 35 D Summary 36 VI Making Changes 37 A The ANZTPA Regime 38 B Clinical Trial Register 42 C Implications of the Proposed Changes 44 VII Administrative Law: Alternative Methods for Obtaining Information 45 A Official Information Act 46 B Ombudsman 50 C Regulations Review Committee 51 VIII Conclusion 53 IX Appendix One 56 X Appendix Two 58 XI Appendix Three 59 XII Bibliography 60 3 Evidence Based Medicine? Access to Information and Medicines Regulation in New Zealand I Introduction A Purpose This paper explores one very important issue in the regulatory regime for medicines in New Zealand and around the world- the deficit of information about medicines available to doctors, patients and independent researchers.
    [Show full text]